Get the Stockscreener App
2.75
1.79%
-0.05
After Hours:
2.75
Galectin Therapeutics Inc stock is traded at $2.75, with a volume of 147.64K.
It is down -1.79% in the last 24 hours and down -7.41% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$2.80
Open:
$2.8
24h Volume:
147.64K
Relative Volume:
0.33
Market Cap:
$177.30M
Revenue:
-
Net Income/Loss:
$-37.30M
P/E Ratio:
-4.6508
EPS:
-0.5913
Net Cash Flow:
$-30.62M
1W Performance:
-11.00%
1M Performance:
-7.41%
6M Performance:
-42.71%
1Y Performance:
+79.74%
1-Day Range:
$2.725
$2.8699
1-Week Range:
$2.63
$3.312
52-Week Range:
$1.12
$7.13
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT vs VRTX, REGN, ALNY, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
2.75 | 177.30M | 0 | -37.30M | -30.62M | -0.5913 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 30.56B | 5.36B | 287.73M | 924.18M | 2.5229 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Wall Street Recap: What makes Galectin Therapeutics Inc stock attractive today - baoquankhu1.vn
Galectin Therapeutics Stock (ISIN: US3631621074) Faces Investor Scrutiny Amid Legal Probe and Earnin - AD HOC NEWS
Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board - The Globe and Mail
Galectin Therapeutics appoints Johns Hopkins neurosurgeon to board By Investing.com - Investing.com India
Galectin Therapeutics Inc. Appoints Henry Brem, M.D. as Independent Director to Board of Directors - marketscreener.com
Sentiment Recap: Is Galectin Therapeutics Inc forming a double bottom2026 Trade Ideas & Consistent Growth Equity Picks - baoquankhu1.vn
Galectin Therapeutics Appoints Dr. Henry Brem to Board, Advancing Belapectin for MASH Cirrhosis and Cancer Therapies - Minichart
Galectin Therapeutics appoints Johns Hopkins neurosurgeon to board - Investing.com
Galectin Therapeutics (GALT) director awarded 60,000 stock options at $3.1600 - Stock Titan
Director Henry Brem joins Galectin (GALT) board and reports zero share ownership - Stock Titan
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. - Bitget
Henry Brem, M.D. joins Galectin Therapeutics (GALT) Board as independent director - Stock Titan
Portfolio Shifts: Whats the outlook for Galectin Therapeutics Incs sectorTake Profit & Accurate Entry/Exit Alerts - baoquankhu1.vn
Recap Report: Is Galectin Therapeutics Inc forming a double bottomQuarterly Market Summary & Accurate Technical Buy Alerts - baoquankhu1.vn
Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps - Yahoo Finance
Take Profit: Does Galectin Therapeutics Inc have a sustainable dividendJuly 2025 Market Mood & Detailed Earnings Play Strategies - baoquankhu1.vn
Panic Selling: Will Galectin Therapeutics Inc outperform its industry peers2025 Price Momentum & Weekly Stock Breakout Alerts - baoquankhu1.vn
Highs Report: Is Galectin Therapeutics Inc forming a double bottomJuly 2025 Selloffs & Weekly Chart Analysis and Guides - baoquankhu1.vn
Buyout Rumor: Can Galectin Therapeutics Inc weather a recessionJuly 2025 Summary & Reliable Intraday Trade Alerts - baoquankhu1.vn
GALT Should I Buy - Intellectia AI
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET - marketscreener.com
Belapectin Phase 3 data: potential first treatment for MASH varices - Stock Titan
GALT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GALT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT - TipRanks
Is Galectin Therapeutics Inc. in a bullish channel2025 Short Interest & Weekly Breakout Watchlists - mfd.ru
Trend Review: Is Galectin Therapeutics Inc in a bullish channelJuly 2025 Decliners & AI Forecast Swing Trade Picks - baoquankhu1.vn
Does Galectin Therapeutics Inc. have a sustainable dividendWeekly Stock Recap & Daily Momentum Trading Reports - mfd.ru
Is Galectin Therapeutics Inc stock a buy or sell2025 Earnings Surprises & Low Risk High Win Rate Picks - baoquankhu1.vn
What is the long term forecast for Galectin Therapeutics Inc. stock2025 Year in Review & Real-Time Buy Signal Notifications - mfd.ru
GALT PE Ratio & Valuation, Is GALT Overvalued - Intellectia AI
Will Galectin Therapeutics Inc. stock deliver long term returns2025 Volatility Report & Safe Capital Allocation Plans - mfd.ru
What’s the outlook for Galectin Therapeutics Inc.’s sectorMarket Growth Review & Fast Exit/Entry Strategy Plans - mfd.ru
Buy Signal: Whats the outlook for Galectin Therapeutics Incs sectorPortfolio Return Report & AI Based Trade Execution Alerts - baoquankhu1.vn
Is Galectin Therapeutics Inc. stock a dividend growth opportunityQuarterly Profit Summary & Weekly High Conviction Trade Ideas - mfd.ru
Short Covering: How is MLKN managing supply chain issues2025 Trading Recap & Fast Moving Stock Watchlists - baoquankhu1.vn
Aug Chart Watch: Is Galectin Therapeutics Inc gaining market shareJuly 2025 Recap & Accurate Intraday Trade Tips - baoquankhu1.vn
Galectin Therapeutics Inc.'s (NASDAQ:GALT) market cap dropped US$39m last week; Individual investors bore the brunt - simplywall.st
Can Galectin Therapeutics Inc expand into new marketsJobs Report & Real-Time Volume Analysis - baoquankhu1.vn
Meme Stocks: Will Galectin Therapeutics Inc outperform its industry peersMarket Activity Report & Expert Approved Momentum Ideas - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galectin Therapeutics Inc.GALT - yourwyominglink.com
Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are retail investors with 55% stake, while 20% is held by insiders - Yahoo Finance
Moving Averages: What is the Moat Score of WVVIPBuy Signal & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Analysis Recap: Can Galectin Therapeutics Inc be the next market leaderTrade Entry Report & Smart Investment Allocation Insights - baoquankhu1.vn
Portfolio Update: Is DNAWS a potential multi baggerEarnings Beat & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Update - MarketBeat
Galectin Therapeutics Under Investigation, Stock Plummets 28.9% - Intellectia AI
Is Galectin Therapeutics Inc. gaining market shareJuly 2025 Analyst Calls & Safe Entry Point Identification - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Galectin Therapeutics Inc. (GALT) And Encourages Shareholders to Reach Out - ACCESS Newswire
Insider Buy: Can BROG navigate macro headwindsWeekly Investment Summary & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Growth Review: Is Galectin Therapeutics Inc stock affected by interest rate hikesQuarterly Earnings Report & Daily Growth Stock Investment Tips - Bộ Nội Vụ
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):